癌症研究
黑色素瘤
免疫系统
免疫检查点
T细胞
髓样
免疫疗法
医学
封锁
免疫学
受体
内科学
作者
João Conniot,Anna Scomparin,Carina Peres,Eilam Yeini,Sabina Pozzi,Ana I. Matos,Ron Kleiner,Liane I.F. Moura,Eva Zupančič,Ana S. Viana,Hila Doron,Pedro M. P. Góis,Neta Erez,Steffen Jung,Ronit Satchi‐Fainaro,Helena F. Florindo
标识
DOI:10.1038/s41565-019-0512-0
摘要
A low response rate, acquired resistance and severe side effects have limited the clinical outcomes of immune checkpoint therapy. Here, we show that combining cancer nanovaccines with an anti-PD-1 antibody (αPD-1) for immunosuppression blockade and an anti-OX40 antibody (αOX40) for effector T-cell stimulation, expansion and survival can potentiate the efficacy of melanoma therapy. Prophylactic and therapeutic combination regimens of dendritic cell-targeted mannosylated nanovaccines with αPD-1/αOX40 demonstrate a synergism that stimulates T-cell infiltration into tumours at early treatment stages. However, this treatment at the therapeutic regimen does not result in an enhanced inhibition of tumour growth compared to αPD-1/αOX40 alone and is accompanied by an increased infiltration of myeloid-derived suppressor cells in tumours. Combining the double therapy with ibrutinib, a myeloid-derived suppressor cell inhibitor, leads to a remarkable tumour remission and prolonged survival in melanoma-bearing mice. The synergy between the mannosylated nanovaccines, ibrutinib and αPD-1/αOX40 provides essential insights to devise alternative regimens to improve the efficacy of immune checkpoint modulators in solid tumours by regulating the endogenous immune response.
科研通智能强力驱动
Strongly Powered by AbleSci AI